Held by 1 specialist biotech fund
Signal Note: Avoro Exit from AUTL
Avoro's complete exit from Autolus signals loss of conviction in the CAR-T franchise, likely driven by underwhelming commercial traction in relapsed/refractory B-cell lymphoma (autol's lead indication) or competitive positioning against Gilead/Juno in an increasingly commoditized space. Cash runway and upcoming data readouts should be monitored as potential near-term catalysts for dilution; cross-check whether other specialist biotech funds (Efung, Cormorant) have similarly reduced exposure to confirm thesis convergence.